Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 31, 2021 08:00 ET | Source: Oncology Pharma, Inc.

Oncology Pharma Has Provided Initial Funding to NanoSmart Pharmaceuticals to Conduct Feasibility Studies for Initial Phases of IND-Enabling Activities

SAN FRANCISCO, CA, March 31, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Oncology Pharma, Inc. (OTC: ONPH) is pleased to announce that it has provided the initial financing for the initiation of...
March 16, 2021 08:00 ET | Source: Oncology Pharma, Inc.

Oncology Pharma Reveals Strategic Plans for Company Growth and Focus

SAN FRANCISCO, CA, March 16, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Oncology Pharma, Inc. (OTC: ONPH) revealed today the Company’s plans for growth and development of its intellectual property...
February 22, 2021 08:00 ET | Source: Oncology Pharma, Inc.

Oncology Pharma Extends Licensing Agreement with NanoSmart Pharmaceuticals, Inc. for Veterinary Oncology

SAN FRANCISCO, CA, Feb. 22, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Oncology Pharma, Inc. (OTC: ONPH) is pleased to announce that it has extended a world-wide Licensing Agreement with NanoSmart...
February 16, 2021 08:00 ET | Source: Oncology Pharma, Inc.

Oncology Pharma is Pleased to Welcome New Chairman to Its Scientific Advisory Board

SAN FRANCISCO, CA, Feb. 16, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Oncology Pharma, Inc. (OTC: ONPH) is pleased to announce that Dr. Henry Smith has accepted the role of Chairman of the...
February 03, 2021 08:30 ET | Source: Oncology Pharma, Inc.

Oncology Pharma Extends Its Licensing Agreement with NanoSmart Pharmaceuticals, Inc. for Human Oncology

SAN FRANCISCO, CA, Feb. 03, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Oncology Pharma, Inc. (OTC: ONPH) is pleased to announce that it has extended its Licensing Agreement with NanoSmart...
April 06, 2020 08:00 ET | Source: Oncology Pharma, Inc.

Oncology Pharma and Kalos Therapeutics Expand Licensing Agreement for Exploring Kalos's Anti-Cancer Lead Drug in Treating COVID-19

SAN FRANCISCO, CA, April 06, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE ‒ Oncology Pharma, Inc. (OTCPK: ONPH) and Kalos Therapeutics (“Kalos”) announced today that the companies amended the terms of...
December 26, 2019 22:15 ET | Source: Oncology Pharma, Inc.

CORRECTION: Oncology Pharma Receives LOI for Financing for US$ 38.4M from SCP Investment Partners, Ltd

SAN FRANCISCO, CA, Dec. 26, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – ONCOLOGY PHARMA, INC. (OTCPK: ONPH) is pleased to announce that it has received a letter of intent dated December 20th to...
December 23, 2019 07:00 ET | Source: Oncology Pharma, Inc.

Oncology Pharma Receives LOI for Financing for US$ 38.4M from SCP Partners Ltd

SAN FRANCISCO, CA, Dec. 23, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – ONCOLOGY PHARMA, INC. (OTCPK: ONPH) is pleased to announce that it has received a letter of intent dated December 20th to...
August 19, 2019 08:00 ET | Source: Oncology Pharma, Inc.

Oncology Pharma Signed a Letter of Intent with Kalos Therapeutics for an Exclusive World-Wide Licence and Co-Devlopent of Its Broad-Spectrum Anti-Cancer Drug, KTH 222

SAN FRANCISCO, CA, Aug. 19, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Oncology Pharma (OTCPK: ONPH) is pleased to announce that it signed a Letter of Intent with Kalos Therapeutics (Phoenix, AZ)...
July 15, 2019 07:30 ET | Source: Oncology Pharma, Inc.

Oncology Pharma Appoints Stefan Gruenwald (MD. Ph.D) as an Advisor on its Advisory Board

SAN FRANCISCO, CA, July 15, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Oncology Pharma, Inc. (OTCPK: ONPH) is pleased and honored to announce the appointment of Stefan Gruenwald (MD. Ph.D) to its...

Next Page keyboard_arrow_right